Drug development

It’s no great revelation that the biotech funding model is broken, yet the market for the industry’s drugs has never been greater. So where is the fix, asks Nuala Moran.

As life sciences investors shy away from drug development and opt for lower-risk devices and diagnostics, what can Europe learn from Israel’s experience?

GlaxoSmithKline (GSK) and Pfizer are spinning out all HIV/AIDS-related R&D and marketed drugs into a separate, jointly-controlled company.

GlaxoSmithKline is to place over 500 granted patents, and over 300 pending applications, into a pool to help others to develop medicines for neglected diseases.